---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-24-000090"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2024-08-15T23:59:59+00:00"
generated_at: "2026-05-31T09:03:20.992634+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "low"
source: SEC EDGAR
---

# Instil Bio provides SYN-2510 program overview in investor presentation

## Summary
- Company furnished presentation detailing its SYN-2510 program as of August 2024.
- No specific clinical data, milestones, or financial projections disclosed in the filing.
- The program overview does not include any changes to previously disclosed guidance or plans.

## SEC filing metadata
- accession: 0001789769-24-000090
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2024-08-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976924000090/0001789769-24-000090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976924000090/til-20240815.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-24-000090
- JSON: https://secwatch.observer/filing/0001789769-24-000090.json
- Plain text: https://secwatch.observer/filing/0001789769-24-000090.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.